Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)
Registered Office:
3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6,
Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills,
Hyderabad, Shaikpet, Telangana, India-500033
T: +91 40 23635000,
E: investorrelations@viyash.com
Website: www.viyash.com
CIN: L99999TS1985PLC196357

November 13, 2026

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East),
Mumbai - 400 051

Scrip code: 512529

Symbol: VIYASH

Dear Sir/ Madam,

Subject: Outcome of Board Meeting held on November 13, 2026

We refer to our intimation dated November 02, 2026, regarding the meeting of the Board of Directors ("Board") of the Company scheduled to be held on Friday, November 13, 2026.

Pursuant to the Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements Regulations), 2015 (**"SEBI Listing Regulations"**) read with applicable SEBI circular(s), we would like to inform you that the Board at its Meeting held today i.e., on Friday, November 13, 2026, *inter-alia,* considered and approved the Unaudited Standalone and Consolidated Financial Results along with Independent Auditor's Limited Review Report for the quarter and half year ended September 30, 2026.

In this regard, please find enclosed the following:

a) Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026.
b) Independent Auditor's Limited Review Report for the quarter and half year ended September 30, 2026.

The Board Meeting commenced at 3:30 p.m. and concluded at 5:15 p.m.

The Trading window for dealing in the Company's securities shall remain closed until 48 hours from this announcement.

We request you to kindly take the above on record.

Thank you,

Yours faithfully,
For **Viyash Scientific Limited**
(Formerly known as Sequent Scientific Limited)

YOSHITA SUSMIT VORA
Digitally signed by YOSHITA SUSMIT VORA
Date: 2026.11.13 17:23:43 +05'30'

Yoshita Vora
Company Secretary & Compliance Officer
Encl: as above

Viyash

Viyash Scientific Limited (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.
E-mail: investorrelations@viyash.com, E-mail: info@viyash.com, Website: www.viyash.com Tel No.: +91 40 23635000

CIN: L99999TS1985PLC196357

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2026

(₹ in Million)

Sr. No.	Particulars	3 months ended 30-September-2026	Preceeding 3 months ended 30-June-2026	Corresponding 3 months ended in previous period 30-September-2025	Year to date for current period ended 30-September-2026	Corresponding year to date for previous period ended 30-September-2025	Previous year ended 31-March-2026
		Unaudited	Unaudited	Unaudited (Restated) (refer note 3)	Unaudited	Unaudited (Restated) (refer note 3)	Audited
I	Revenue from operations	3,906.50	3,536.90	3,397.50	7,443.40	6,679.30	13,820.60
II	Other income	107.40	145.90	173.20	253.30	302.20	662.60
III	**Total income (I+II)**	**4,013.90**	**3,682.80**	**3,570.70**	**7,696.70**	**6,981.50**	**14,483.20**
IV	**Expenses**						
	(a) Cost of materials consumed	2,090.10	1,653.10	1,559.90	3,743.20	2,886.30	5,998.20
	(b) Purchases of stock-in-trade	85.20	34.20	45.40	119.40	47.60	284.10
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(346.00)	(55.00)	(60.20)	(401.00)	93.40	(43.60)
	(d) Employee benefits expenses (refer note 5)	899.80	706.40	523.90	1,606.20	1,062.00	2,137.50
	(e) Finance costs	21.70	14.40	41.00	36.10	101.20	162.10
	(f) Depreciation and amortisation expenses	162.00	324.10	309.00	486.10	617.90	1,241.50
	(g) Other expenses	782.00	726.70	808.00	1,508.70	1,575.00	3,099.10
	Total expenses (IV)	**3,694.80**	**3,403.90**	**3,227.00**	**7,098.70**	**6,383.40**	**12,878.90**
V	**Profit before tax and exceptional items (III-IV)**	**319.10**	**278.90**	**343.70**	**598.00**	**598.10**	**1,604.30**
VI	Exceptional items (refer note 4)	-	-	(17.00)	-	(29.50)	(442.10)
VII	**Profit before tax (V-VI)**	**319.10**	**278.90**	**326.70**	**598.00**	**568.60**	**1,162.20**
VIII	**Tax expense / (credit)**						
	(a) Current tax	87.00	46.20	147.10	133.20	259.20	152.10
	(b) Deferred tax	(1.50)	23.50	(48.80)	22.00	(92.00)	251.40
	Total tax expense / (credit) (VIII)	**85.50**	**69.70**	**98.30**	**155.20**	**167.20**	**403.50**
IX	**Profit after tax (VII-VIII)**	**233.60**	**209.20**	**228.40**	**442.80**	**401.40**	**758.70**
X	**Other comprehensive income / (loss)**						
	Items that will not be reclassified to profit or loss						
	(a) Re-measurement gain / (loss) on defined benefits plans	(0.20)	(3.70)	1.00	(3.90)	1.00	(13.00)
	(b) Fair value gain / (loss) from investment in equity instruments	-	0.10	(0.10)	0.10	-	(0.20)
	(c) Income tax relating to items that will not be reclassified to profit or loss	0.10	0.90	(0.30)	1.00	(0.30)	3.40
	Total other comprehensive income / (loss) (net of tax)	**(0.10)**	**(2.70)**	**0.60**	**(2.80)**	**0.70**	**(9.80)**
XI	**Total comprehensive income net of tax (IX+X)**	**233.50**	**206.50**	**229.00**	**440.00**	**402.10**	**748.90**
XII	Equity share capital (face value of ₹ 2 each) (refer note 3)	883.20	873.70	503.30	883.20	503.30	873.70
XIII	Other equity						31,017.00
XIV	**Earnings per equity share: (face value of ₹ 2 each) (not annualised)**						
	(1) Basic in ₹ (refer note 7)	0.53	0.48	0.53	1.01	0.93	1.75
	(2) Diluted in ₹ (refer note 7)	0.52	0.47	0.52	0.98	0.91	1.72
	See accompanying notes to unaudited standalone financial results						

Viyash Scientific Limited

Viyash

Viyash Scientific Limited (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290,Road No. 6, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.

E-mail: investorrelations@viyash.com, E-mail: info@viyash.com, Website: Website: www.viyash.com Tel No.: +91 40 23635000

CIN: L99999TS1985PLC196357

STATEMENT OF UNAUDITED STANDALONE BALANCE SHEET AS AT 30 SEPTEMBER 2026

(₹ in Million)

Sr. No.	Particulars	As at 30-September-2026 Unaudited	As at 31-March-2026 Audited
A	**ASSETS**		
I	**Non-current assets**		
(a)	Property, plant and equipment (PPE)	8,328.90	7,926.90
(b)	Right-of-use assets (ROU)	107.90	100.30
(c)	Capital work-in-progress	175.70	554.20
(d)	Goodwill	3,347.00	3,347.00
(e)	Other intangible assets	44.80	249.80
(f)	Financial assets		
	(i) Investments		
	(a) Investments in subsidiaries (refer note 6)	13,797.60	9,768.00
	(b) Other investments	0.20	0.20
	(ii) Loans (refer note 6)	1,957.40	4,739.70
	(iii) Other financial assets	127.40	119.10
(g)	Income tax assets (net)	91.00	91.00
(h)	Other non-current assets	41.20	29.70
	Total non-current assets	**28,019.10**	**26,925.90**
II	**Current assets**		
(a)	Inventories	3,713.80	2,928.70
(b)	Financial assets		
	(i) Investments	0.60	0.50
	(ii) Trade receivables	5,774.40	5,542.60
	(iii) Cash and cash equivalents	103.40	209.70
	(iv) Bank balances other than (iii) above	123.40	140.50
	(v) Loans	-	0.10
	(vi) Other financial assets	6.00	7.90
(c)	Other current assets	1,021.90	794.50
	Total current assets	**10,743.50**	**9,624.50**
	Total assets	**38,762.60**	**36,550.40**
B	**EQUITY AND LIABILITIES**		
I	**Equity**		
(a)	Equity share capital	883.20	873.70
(b)	Other equity	32,563.60	31,017.00
	Total equity	**33,446.80**	**31,890.70**
II	**Liabilities**		
1.	**Non-current liabilities**		
(a)	Financial liabilities		
	(i) Borrowings	41.50	63.20
	(ii) Lease liabilities	9.70	0.20
	(iii) Other financial liabilities	10.80	10.80
(b)	Provisions	177.90	173.10
(c)	Deferred tax liabilities (net)	275.10	254.10
(d)	Other non-current liabilties	-	0.60
	Total non-current liabilities	**515.00**	**502.00**
2.	**Current liabilities**		
(a)	Financial liabilities		
	(i) Borrowings	479.10	258.00
	(ii) Lease liabilities	2.40	4.10
	(iii) Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	282.00	240.40
	Total outstanding dues of creditors other than micro enterprises and small enterprises	3,444.40	2,865.10
	(iv) Other financial liabilities	197.60	473.70
(b)	Provisions	62.80	61.30
(c)	Current tax liabilities (net)	209.30	84.80
(d)	Other current liabilities	123.20	170.30
	Total current liabilities	**4,800.80**	**4,157.70**
	Total liabilities	**5,315.80**	**4,659.70**
	Total equity and liabilities	**38,762.60**	**36,550.40**
	See accompanying notes to unaudited standalone financial results		

Viyash Scientific Limited

Viyash

Viyash Scientific Limited (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.

E-mail: investorrelations@viyash.com, E-mail: info@viyash.com, Website: www.viyash.com Tel No.: +91 40 23635000

CIN: L99999TS1985PLC196357

UNAUDITED STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30 SEPTEMBER 2026

(₹ in Million)

Particulars	Half year ended 30-September-2026	Half year ended 30-September-2025
	Unaudited	Unaudited (Restated) {refer note 3}
Cash flows from operating activities		
Net profit before tax	598.00	568.60
Adjustments for:		
Depreciation and amortisation expenses	486.10	617.90
Property plant and equipment written off	0.40	-
Allowances / (write-back) for doubtful trade receivables	(10.20)	39.40
Gain on derecognition of leases	-	(1.20)
Unrealised foreign exchange gain	(28.50)	(41.80)
Finance costs	36.10	101.20
Interest income	(185.40)	(201.80)
(Gain) / loss on sale of Property plant and equipment (net) and transfer of leasehold rights	(3.80)	40.90
Expenses pertaining to share-based payments	592.50	81.70
Exceptional items	-	29.50
Operating profit before working capital changes	**1,485.20**	**1,234.40**
Changes in working capital		
(Increase) / Decrease in trade receivables, advance to suppliers and other assets	(376.50)	34.50
(Increase) / Decrease in inventories	(785.10)	65.60
Increase in trade payables, advances from customers, other liabilities and provisions	342.00	89.30
Net changes in working capital	**(819.60)**	**189.40**
Cash generated from operations	**665.60**	**1,423.80**
Income taxes paid, net of refunds	(14.30)	(186.10)
Net cash generated from operating activities (A)	**651.30**	**1,237.70**
Cash flows from investing activities		
Purchase of PPE, capital work in progress, capital creditors, capital advances and intangible assets	(358.30)	(493.90)
Proceeds from disposal of PPE, assets held for sale and transfer of leasehold rights	9.70	85.30
(Investments in) / Redemption of fixed deposits (net)	17.10	(33.80)
Loans given to subsidiary company	(1,062.40)	(175.00)
Interest received	9.60	29.60
Net cash used in investing activities (B)	**(1,384.30)**	**(587.80)**
Cash flows from financing activities		
Proceeds in respect of allotment of employee stock options	464.80	119.90
Proceeds from long-term borrowings	2.50	3.40
Repayment of long-term borrowings	(26.80)	(132.70)
Proceeds from / (Repayment of) short-term borrowings (net)	222.60	(552.60)
Payment of lease liabilities	(4.40)	(11.30)
Interest and other borrowing cost paid	(32.00)	(101.00)
Net cash generated from / (used in) financing activities (C)	**626.70**	**(674.30)**
Net increase / (decrease) in cash and cash equivalents during the period (A+B+C)	**(106.30)**	**(24.40)**
Cash and cash equivalents at the beginning of the period	209.70	157.90
Cash and cash equivalents at the end of the period	**103.40**	**133.50**
See accompanying notes to unaudited standalone financial results		

Viyash Scientific Limited

Viyash Scientific Limited (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.
E-mail: investorrelations@viyash.com, E-mail: info@viyash.com, Website: www.viyash.com Tel No.: +91 40 23635000

CIN: L99999TS1985PLC196357

Notes:

1 The above statement of unaudited standalone financial results of Viyash Scientific Limited has been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI"). These results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 13 November 2026. The Statutory Auditors have carried out a limited review of the unaudited standalone financial results and issued unmodified reports thereon.

2 The Company is primarily engaged in the business of 'Pharmaceuticals'. There is no separate reportable segment as per Ind AS 108 - "Operating Segments".

3 The Board of Directors of the Company at their meeting held on 26 September 2024 have approved the Composite Scheme of Amalgamation (the Scheme) amongst the Company, Sequent Research Limited (wholly owned subsidiary of the Company), Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, SV Labs Private Limited, Vindhya Organics Private Limited, Genin Life Sciences Private Limited (referred to as 'transferor Companies') in terms of Section 230-232 and other applicable provisions of Companies Act, 2013.

The Hon'ble National Company Law Tribunal (NCLT), Hyderabad vide its order dated 18 November 2025 sanctioned the Scheme with an Appointed date of 01 April 2025. The Scheme has become effective on 16 December 2025 upon filing of the certified true copy of the order with the Registrar of Companies Hyderabad.As per the terms of the Scheme, the Company has alloted 18,19,21,827 fully paid-up equity shares of face value of ₹ 2 each, as per the share exchange ratio of 56 fully paid-up equity shares of face value of ₹ 2 each of the Company for every 100 fully paid-up equity shares of face value of ₹ 10 each held by eligible shareholders of erstwhile Viyash Life Sciences Private Limited as on the record date. The Company has also alloted 2,03,41,257 warrants under the Scheme to eligible warrant holder of erstwhile Viyash Life Sciences Private Limited as per the Warrant exchange ratio of 56 warrants of the Company for every 100 warrants held in erstwhile Viyash Life Sciences Private Limited and received a consideration of ₹ 925.20 million during the previous year ended 31 March 2026 (representing 25% on Warrant consideration as per the Scheme).

The Company has accounted for the business combination transaction using the 'Pooling of interest method' as given under Appendix C to Ind AS 103, 'Business Combinations of Entities under Common Control', in accordance with the accounting treatment prescribed in the Scheme. Accordingly, the financial results of the company in respect of the corresponding prior periods have been restated as if the aforesaid business combination had occurred from the beginning of the preceding period (i.e. 01 April 2024) as per below :

a) Details of revenue and profit restated due to the Scheme of Amalgamation: *(₹ in Million)*

Particulars	Corresponding 3 months ended in previous period 30-September-2025		Corresponding year to date ended in previous period 30-September-2025	
	Reported	Restated	Reported	Restated
Revenue from operations	340.30	3,397.50	751.00	6,679.30
Profit before tax	43.40	326.70	91.20	568.60
Profit after tax	30.80	228.40	64.50	401.40
Total comprehensive income (net of tax)	31.50	229.00	65.20	402.10
Basic earnings per equity share (in ₹) (not annualised)	0.12	0.53	0.26	0.93
Diluted earnings per equity share (in ₹) (not annualised)	0.12	0.52	0.25	0.91

b) Details of Cashflow restated due to the Scheme of Amalgamation: *(₹ in Million)*

Particulars	Period ended 30-September-2025	
	Reported	Restated
Net cash generated from operating activities	291.70	1,237.70
Net cash used in investing activities	(166.30)	(587.80)
Net cash used in financing activities	(118.20)	(674.30)

4 **Exceptional items include:** *(₹ in Million)*

Particulars	Note reference	3 months ended 30-September-2026	Preceeding 3 months ended 30-June-2026	Corresponding 3 months ended in previous period 30-September-2025	Year to date for current period ended 30-September-2026	Corresponding year to date for previous period ended 30-September-2025	Previous year ended 31-March-2026
		Unaudited	Unaudited	Unaudited (Restated) (refer note 3)	Unaudited	Unaudited (Restated) (refer note 3)	Audited
Expenses related to the Scheme of Amalgamation	(a)	-	-	17.00	-	29.50	442.10
Total		**-**	**-**	**17.00**	**-**	**29.50**	**442.10**

(a) The Company has recorded below transaction costs pertaining to Scheme :
(i) Stamp duty recognized on an estimated basis amounting to ₹ 296.50 million for the previous year ended 31 March 2026 payable pursuant to scheme.
(ii) Transactions costs with respect to fees payable to merchant banker in relation to Scheme amounting to ₹ 7.00 million for quarter ended 30 September 2025, ₹17.10 million for half year ended 30 September 2025 and ₹ 107.60 million for the previous year ended 31 March 2026.
(iii) Other transaction costs with respect to fees payable to lawyers and other consultants engaged in relation to the Scheme amounting to ₹ 10.00 million for quarter ended 30 September 2025, ₹ 12.40 million for half year ended 30 September 2025 and ₹38.00 million for the previous year ended 31 March 2026.

5 Pursuant to the Composite Scheme of Amalgamation (refer note 3 above), the Board of Directors and Nomination and Remuneration Committee (NRC) at its meeting held on February 05, 2026 approved the adoption of Viyash Scientific Limited - Employee Stock Option Scheme 2026 ("ESOP Scheme 2026"), subject to receipt of necessary approvals.
During the quarter ended 30 June 2026, on receipt of necessary approvals, Company has granted 13,098,000 employee stock options, representing 2.8% of the post-amalgamation paid-up share capital of the Company under ESOP Scheme 2026. This has resulted in an incremental expense of ₹ 372 million for the quarter ended 30 September 2026 and ₹ 563 million for the half year ended 30 September 2026 (₹ 191 million for the quarter ended 30 June 2026), which has been recognized under 'Employee benefit expense' in the financial results.

6 The Board of Directors, at its meeting held on 11 August 2026, approved an investment of ₹ 4,000.22 million by way of subscription to the rights issue of equity shares of Alivira Animal Health Limited ("AAHL"), a wholly owned subsidiary of the Company. The subscription amount payable towards the said rights issue was settled through adjustment against the intercompany loan previously extended by the Company to AAHL. As AAHL is a wholly owned subsidiary of the Company, this investment did not result in any change in the Company's shareholding percentage in AAHL.

7 Weighted average number of shares considered for calculation of basic and diluted earnings per share for all the periods reported includes the weighted average effect of equity shares and warrants alloted pursuant to the Scheme as described in note 3 above and outstanding share options under employees share option plan.

Viyash Scientific Limited

For Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)

Dr. Hari Babu Bodepudi
Managing Director and Group CEO

Hyderabad, 13 November 2026

S R B C & CO LLP
Chartered Accountants

12th Floor, The Ruby
29 Senapati Bapat Marg
Dadar (West)
Mumbai - 400 028, India
Tel : +91 22 6819 8000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Viyash Scientific Limited (formerly known as Sequent Scientific Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of Viyash Scientific Limited (formerly known as Sequent Scientific Limited) (the "Company") which includes Sequent Scientific Employee Stock Option Plan Trust (the "Trust") for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We draw attention to Note 3 to the accompanying Statement, which describes that pursuant to the Composite Scheme of Amalgamation (the "Scheme") between the Company and SeQuent Research Limited, Viyash Life Sciences Private Limited and its subsidiaries (individually referred to as "Transferor Company"), as approved by the Hon'ble National Company Law Tribunal vide its order dated November 18, 2025, the

S R B C & CO LLP MUMBAI CHARTERED ACCOUNTANTS

Transferor Companies have been amalgamated with the Company. The amalgamation has been accounted for in the manner as prescribed under the Scheme and in accordance with Appendix C of Ind AS 103 - Business Combinations, applicable to business combination of entities under common control. Accordingly, the comparative financial information for the quarter / period ended 30 September 2025 presented in accompanying Statement, has been restated to give effect to the aforesaid amalgamation, as described further in the said note. Our conclusion is not modified in respect of this matter.

6. The accompanying Statement includes unaudited interim financial results and other financial information in respect of Sequent Scientific Employee Stock Option Plan Trust, whose interim financial results and other financial information reflect total assets of Rs. 28.40 million as at September 30, 2026, total revenues of Rs. Nil and Rs. Nil, total net loss after tax of Rs. Nil and Rs. 0.01 million, total comprehensive expense of Rs. Nil and Rs. 0.01 million for the quarter ended September 30, 2026 and period ended on that date respectively and net cash outflow of Rs. 0.03 million for the period from April 01, 2026 to September 30, 2026.

These unaudited interim financial results and other unaudited financial information of the Trust have not been reviewed by any auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of the Trust is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results and other unaudited financial information of the Trust are not material to the Company.

Our conclusion on the Statement in respect of matter stated in paragraph 6 above is not modified with respect to our reliance on the financial results certified by the Management.

For S R B C & CO LLP
Chartered Accountants
ICAI Firm registration number: 324982E/E300003

S R B C & CO LLP * MUMBAI * CHARTERED ACCOUNTANTS

per Anil Jobanputra
Partner
Membership No.: 110759
UDIN: 26110759TYNZTU5123
Place: Mumbai
Date: November 13, 2026

Viyash

Viyash Scientific Limited (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290,Road No. 6, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.
E-mail: investorrelations@viyash.com, E-mail: info@viyash.com, Website: www.viyash.com Tel No.: +91 40 23635000

CIN: L99999TS1985PLC196357

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2026

(₹ in Million)

Sr. No	Particulars	3 months ended 30-September-2026	Preceding 3 months ended 30-June-2026	Corresponding 3 months ended in previous period 30-September-2025	Year to date for current period ended 30-September-2026	Corresponding year to date for previous period 30-September-2025	Previous year ended 31-March-2026
		Unaudited	Unaudited	Unaudited (Restated) {refer note 3}	Unaudited	Unaudited (Restated) {refer note 3}	Audited
I	Revenue from operations	9,879.40	9,463.60	8,503.00	19,343.00	16,419.40	34,203.10
II	Other income	117.80	83.10	74.60	200.90	136.50	435.50
III	**Total income (I+II)**	**9,997.20**	**9,546.70**	**8,577.60**	**19,543.90**	**16,555.90**	**34,638.60**
IV	**Expenses**						
	(a) Cost of materials consumed	4,385.10	4,023.40	3,532.40	8,408.50	6,657.20	13,769.30
	(b) Purchases of stock-in-trade	780.30	653.60	496.80	1,433.90	1,020.00	2,505.90
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(591.30)	(334.50)	(244.70)	(925.80)	(87.50)	(647.90)
	(d) Employee benefits expense (refer note 5)	1,848.30	1,626.50	1,392.00	3,474.80	2,779.90	5,655.00
	(e) Finance costs	137.10	125.10	175.10	262.20	379.40	692.10
	(f) Depreciation and amortisation expenses	453.30	617.70	591.10	1,071.00	1,147.00	2,336.40
	(g) Other expenses	1,791.90	1,696.40	1,586.70	3,488.30	3,152.90	6,378.50
	(h) Net monetary (gain) / loss on hyperinflation economy (refer note 6)	15.70	14.40	7.50	30.10	(29.60)	17.00
	Total expenses (IV)	**8,820.40**	**8,422.60**	**7,536.90**	**17,243.00**	**15,019.30**	**30,706.30**
V	**Profit before tax and exceptional items (III-IV)**	**1,176.80**	**1,124.10**	**1,040.70**	**2,300.90**	**1,536.60**	**3,932.30**
VI	Exceptional items (refer note 4)	-	-	(17.00)	-	(29.50)	(442.10)
VII	**Profit before tax (V-VI)**	**1,176.80**	**1,124.10**	**1,023.70**	**2,300.90**	**1,507.10**	**3,490.20**
VIII	**Tax expense / (credit)**						
	(a) Current tax	335.40	339.80	372.70	675.20	612.80	631.50
	(b) Deferred tax	(5.10)	(8.60)	(78.00)	(13.70)	(203.20)	612.20
	Total tax expense / (credit) (VIII)	**330.30**	**331.20**	**294.70**	**661.50**	**409.60**	**1,243.70**
IX	**Profit after tax (VII-VIII)**	**846.50**	**792.90**	**729.00**	**1,639.40**	**1,097.50**	**2,246.50**
X	**Other comprehensive income / (loss)**						
	Items that will not be reclassified to profit or loss						
	(a) Re-measurement loss on defined benefits plans	3.90	(3.70)	0.40	0.20	0.40	(30.90)
	(b) Fair value gain / (loss) from investment in equity instruments	-	0.10	(0.10)	0.10	-	(0.20)
	(c) Income tax relating to items that will not be reclassified to profit or loss	(1.00)	0.90	(0.30)	(0.10)	(0.30)	7.80
	Items that will be reclassified to profit or loss						
	(a) Exchange differences on translation of foreign operations	25.00	(21.10)	249.70	3.90	474.00	897.70
	(b) Exchange differences on net investment in foreign operations	(33.90)	(39.60)	55.00	(73.50)	175.60	194.60
	Total other comprehensive income / (loss) (net of tax)	**(6.00)**	**(63.40)**	**304.70**	**(69.40)**	**649.70**	**1,069.00**
XI	**Total comprehensive income, net of tax (IX+X)**	**840.50**	**729.50**	**1,033.70**	**1,570.00**	**1,747.20**	**3,315.50**
	Profit attributable to :						
	- Owners of the Company	761.70	658.70	549.10	1,420.40	867.30	1,772.80
	- Non-controlling interest	84.80	134.20	179.90	219.00	230.20	473.70
	Other comprehensive income / (loss) attributable to :						
	- Owners of the Company	(42.30)	(56.20)	219.70	(98.50)	515.90	790.30
	- Non-controlling interest	36.30	(7.20)	85.00	29.10	133.80	278.70
	Total comprehensive income attributable to :						
	- Owners of the Company	719.40	602.50	768.80	1,321.90	1,383.20	2,563.10
	- Non-controlling interest	121.10	127.00	264.90	248.10	364.00	752.40
XII	Equity share capital (face value of ₹ 2 each) (refer note 3)	883.20	873.70	503.30	883.20	503.30	873.70
XIII	Other equity						28,236.90
XIV	**Earnings per equity share: (face value of ₹ 2 each) (not annualised)**						
	(1) Basic in ₹ (refer note 8)	1.74	1.51	1.28	3.25	2.01	4.09
	(2) Diluted in ₹ (refer note 8)	1.69	1.47	1.26	3.14	1.98	4.01
	See accompanying notes to the unaudited consolidated financial results						

Viyash Scientific Limited

Viyash

Viyash Scientific Limited (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290,Road No. 6, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.

E-mail: investorrelations@viyash.com, E-mail: info@viyash.com, Website: www.viyash.com Tel No.: +91 40 23635000

CIN: L99999TS1985PLC196357

STATEMENT OF UNAUDITED CONSOLIDATED BALANCE SHEET AS AT 30 SEPTEMBER 2026

(₹ in Million)

Sr. No.	Particulars	As at 30-September-2026	As at 31-March-2026
		Unaudited	Audited
A	**ASSETS**		
I	**Non-current assets**		
(a)	Property, plant and equipment (PPE)	10,957.30	10,634.10
(b)	Right-of-use assets (ROU)	716.70	744.90
(c)	Capital work-in-progress	421.30	687.30
(d)	Goodwill	8,771.90	8,687.20
(e)	Other intangible assets	614.30	963.20
(f)	Intangible assets under development	14.90	17.30
(g)	Financial assets		
	(i) Investments	0.20	0.20
	(ii) Other financial assets	210.60	221.60
(h)	Deferred tax assets (net)	882.20	833.70
(i)	Income tax assets (net)	106.20	140.30
(j)	Other non-current assets	958.90	808.60
	Total non-current assets	**23,654.50**	**23,738.40**
II	**Current assets**		
(a)	Inventories	9,211.10	8,032.00
(b)	Financial assets		
	(i) Investments	0.60	0.50
	(ii) Trade receivables	11,672.20	10,452.30
	(iii) Cash and cash equivalents	4,925.40	2,557.60
	(iv) Bank balances other than (iii) above	123.40	139.50
	(v) Loans	0.60	1.20
	(vi) Other financial assets	19.90	19.70
(c)	Income tax assets (net)	51.40	47.40
(d)	Other current assets	1,651.50	1,295.30
	Total current assets	**27,656.10**	**22,545.50**
	Total assets	**51,310.60**	**46,283.90**
B	**EQUITY AND LIABILITIES**		
I	**Equity**		
(a)	Equity share capital	883.20	873.70
(b)	Other equity	30,763.50	28,236.90
(c)	Non-controlling interest	2,284.70	2,036.70
	Total equity	**33,931.40**	**31,147.30**
II	**Liabilities**		
1	**Non-current liabilities**		
(a)	Financial Liabilities		
	(i) Borrowings	524.00	3,021.00
	(ii) Lease liabilities	357.70	384.40
	(iii) Other financial liabilities	10.80	10.80
(b)	Provisions	414.40	403.20
(c)	Deferred tax liabilities (net)	354.70	327.70
(d)	Other non-current liabilities	1,524.00	1,530.50
	Total non-current liabilities	**3,185.60**	**5,677.60**
2	**Current liabilities**		
(a)	Financial liabilities		
	(i) Borrowings	4,786.30	1,337.20
	(ii) Lease liabilities	173.90	155.00
	(iii) Trade payables	7,118.70	5,972.70
	(iv) Other financial liabilities	695.20	899.40
(b)	Provisions	151.60	157.10
(c)	Current tax liabilities (net)	615.00	240.60
(d)	Other current liabilities	652.90	697.00
	Total current liabilities	**14,193.60**	**9,459.00**
	Total liabilities	**17,379.20**	**15,136.60**
	Total equity and liabilities	**51,310.60**	**46,283.90**
	See accompanying notes to the unaudited consolidated financial results		

Viyash Scientific Limited

Viyash

Viyash Scientific Limited (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290,Road No. 6, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.

E-mail: investorrelations@viyash.com, E-mail: info@viyash.com, Website: www.viyash.com Tel No.: +91 40 23635000

CIN: L99999TS1985PLC196357

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED 30 SEPTEMBER 2026

(₹ in Million)

Particulars	Half year ended 30-Sep-2026	Half year ended 30-Sep-2025
	Unaudited	Unaudited (Restated) {refer note 3}
Cash flow from operating activities		
Net profit before tax	**2,300.90**	**1,507.10**
Adjustments for:		
Depreciation and amortisation expenses	1,071.00	1,147.00
Unrealised foreign exchange gain	(23.40)	(33.50)
Bad trade receivables written off	16.80	66.40
Allowances / (write-back) for doubtful trade receivables	(15.90)	5.60
Finance costs	262.20	379.40
Interest income	(85.40)	(29.40)
(Gain) / Loss on sale of Property plant and equipment (net) and transfer of leasehold rights	(8.00)	18.70
Gain on sale of investments	-	(5.10)
Gain on derecognition of leases	-	(14.80)
Property, plant and equipment written off	0.40	-
Bad debts earlier written off, now recovered	(43.20)	-
Exceptional Items	-	29.50
Hyperinflation Impact	30.10	20.40
Expenses pertaining to share-based payments	666.50	229.60
Operating profit before working capital changes	**4,172.00**	**3,320.90**
Changes in working capital		
(Increase) / Decrease in trade receivables, advances to suppliers and other assets	(1,801.60)	(1,397.50)
(Increase) / Decrease in inventories	(1,219.40)	(176.81)
Increase / (Decrease) in trade payables, advances from customers and other liabilities and provisions	948.60	134.20
Net changes in working capital	**(2,072.40)**	**(1,440.11)**
Cash generated from operations	**2,099.60**	**1,880.79**
Income taxes paid, net of refunds	(272.20)	(368.10)
Net cash generated from operating activities (A)	**1,827.40**	**1,512.69**
Cash flow from investing activities :		
Purchase of PPE, capital work in progress, capital creditors, capital advances and intangible assets	(673.80)	(696.00)
Proceeds from disposal of PPE, assets held for sale and transfer of leasehold rights	16.90	116.20
(Investments in) / Redemption of fixed deposits (net)	17.10	26.30
Proceeds from sale of current investments (net)	-	5.20
Interest received	86.50	34.10
Net cash used in investing activities (B)	**(553.30)**	**(514.20)**
Cash flow from financing activities		
Proceeds in respect of allotment of employee stock options	464.80	119.90
Proceeds from long-term borrowings	552.40	3.40
Repayment of long-term borrowings	(54.90)	(179.90)
Proceeds / (Repayment) of short-term borrowings (net)	405.60	(348.30)
Payment of lease liabilities	(57.60)	(99.00)
Interest and other borrowing cost paid	(216.60)	(386.40)
Dividend distribution to non-controlling interest (NCI)	-	(23.90)
Net cash generated from/ (used in) financing activities (C)	**1,093.70**	**(914.20)**
Net increase in cash and cash equivalents during the period (A+B+C)	2,367.80	84.29
Cash and cash equivalents at beginning of the period	2,557.60	1,403.00
Cash and cash equivalents at end of the period	**4,925.40**	**1,487.29**
See accompanying notes to the unaudited consolidated financial results		

Viyash Scientific Limited

Viyash

Viyash Scientific Limited (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290,Road No. 6, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.
E-mail: investorrelations@viyash.com, E-mail: info@viyash.com, Website: www.viyash.com Tel No.: +91 40 23635000
CIN: L99999TS1985PLC196357

Notes:

1. The above statement of unaudited consolidated financial results of Viyash Scientific Limited (the "Holding Company" or the "Company"), and its subsidiaries (the Holding Company and its subsidiaries together referred to as the "Group") has been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI"). These results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 13 November 2026. The Statutory Auditors have carried out a limited review of the unaudited consolidated financial results and issued unmodified reports thereon.

2. The Group is primarily engaged in the business of 'Pharmaceuticals'. There is no separate reportable segment as per Ind AS 108- Operating Segments.

3. The Board of Directors of the Company at their meeting held on 26 September 2024 have approved the Composite Scheme of Amalgamation (the 'Scheme') amongst the Company, erstwhile Sequent Research Limited (wholly owned subsidiary of the Company), Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, SV Labs Private Limited, Vindhya Organics Private Limited, Genin Life Sciences Private Limited (referred to as 'transferor Companies') in terms of Section 230-232 and other applicable provisions of Companies Act, 2013.

The Hon'ble National Company Law Tribunal (NCLT), Hyderabad vide its order dated 18 November 2025 sanctioned the Scheme with an Appointed date of 01 April 2025. The Scheme has become effective on 16 December 2025 upon filing of the certified true copy of the order with the Registrar of Companies Hyderabad. As per the terms of the Scheme, the Company has allotted 18,19,21,827 fully paid-up equity shares of face value of ₹ 2 each, as per the share exchange ratio of 56 fully paid-up equity shares of face value of ₹ 2 each of the Company for every 100 fully paid-up equity shares of face value of ₹ 10 each held by eligible shareholders of erstwhile Viyash Life Sciences Private Limited as on the record date. The Company has also allotted 2,03,41,257 warrants under the Scheme to eligible warrant holder of erstwhile Viyash Life Sciences Private Limited as per the Warrant exchange ratio of 56 warrants of the Company for every 100 warrants held in erstwhile Viyash Life Sciences Private Limited and received a consideration of ₹ 925.20 million during the year ended 31 March 2026 (representing 25% on Warrant consideration as per the Scheme).

The Company has accounted for the business combination transaction using the 'Pooling of interest method' as given under Appendix C to Ind AS 103, 'Business Combinations of Entities under Common Control', in accordance with the accounting treatment prescribed in the Scheme. Accordingly, the consolidated financial results of the Group in respect of the corresponding prior periods have been restated as if the aforesaid business combination had occurred from the beginning of the preceding period (i.e. 01 April 2024) as per below:

(a) Details of revenue and profit restated due to the Scheme of Amalgamation: *(₹ in Million)*

Particulars	Corresponding 3 months ended in previous period 30-September-2025		Corresponding year to date for previous period ended 30-September-2025	
	Reported	Restated	Reported	Restated
Revenue from operations	4,239.90	8,503.00	8,654.10	16,419.40
Profit before tax	271.60	1,023.70	526.80	1,507.10
Profit after tax	196.00	729.00	371.70	1,097.50
Total comprehensive income (net of tax)	339.50	1,033.70	832.70	1,747.20
Basic earnings per equity share (in ₹) (not annualised)	0.59	1.28	1.16	2.01
Diluted earnings per equity share (in ₹) (not annualised)	0.58	1.26	1.14	1.98

(b) Details of Cashflow restated due to the Scheme of Amalgamation: *(₹ in Million)*

Particulars	Period ended 30-September-2025	
	Reported	Restated
Net cash generated from operating activities	449.00	1,512.69
Net cash used in investing activities	(42.20)	(514.20)
Net cash used in financing activities	(325.70)	(914.20)

4. Exceptional items include: *(₹ in Million)*

Particulars	Note Reference	3 months ended 30-September-2026	Preceding 3 months ended 30-June-2026	Corresponding 3 months ended in previous period 30-September-2025	Year to date for current period ended 30-September-2026	Corresponding year to date for previous period 30-September-2025	Previous year ended 31-March-2026
		Unaudited	Unaudited	Unaudited (Restated) {refer note 3}	Unaudited	Unaudited (Restated) {refer note 3}	Audited
Expenses related to Scheme of Amalgamation	(a)	-	-	17.00	-	29.50	442.10
Total		**-**	**-**	**17.00**	**-**	**29.50**	**442.10**

(a) The Group has recorded below transaction costs pertaining to Scheme :
(i) Stamp duty recognized on an estimated basis amounting to ₹ 296.50 million for the previous year ended 31 March 2026 payable pursuant to scheme.
(ii) Transactions costs with respect to fees payable to merchant banker in relation to Scheme amounting to ₹ 7.00 million for quarter ended 30 September 2025, ₹17.10 million for half year ended 30 September 2025 and ₹ 107.60 million for the previous year ended 31 March 2026.
(iii) Other transaction costs with respect to fees payable to lawyers and other consultants engaged in relation to the Scheme amounting to ₹ 10.00 million for quarter ended 30 September 2025, ₹ 12.40 million for half year ended 30 September 2025 and ₹38.00 million for the previous year ended 31 March 2026.

5. Pursuant to the Composite Scheme of Amalgamation (refer note 3 above), the Board of Directors and Nomination and Remuneration Committee (NRC) at its meeting held on February 05, 2026 approved the adoption of Viyash Scientific Limited - Employee Stock Option Scheme 2026 ("ESOP Scheme 2026"), subject to receipt of necessary approvals.
During the quarter ended 30 June 2026, on receipt of necessary approvals, Company has granted 13,098,000 employee stock options, representing 2.8% of the post-amalgamation paid-up share capital of the Company under ESOP Scheme 2026. This has resulted in an incremental expense of ₹ 377 million for the quarter ended 30 September 2026 and ₹ 570 million for the half year ended 30 September 2026 (₹ 193 million for the quarter ended 30 June 2026), which has been recognized under "Employee benefit expense" in the financial results.

6. The Group has applied IND AS 29 'Accounting for Hyperinflationary economies' on Turkish subsidiaries, since the Turkish Lira is a functional currency of these subsidiaries in Turkey which is a hyperinflationary economy. In preparing the consolidated financial results, the non-monetary assets (includes goodwill, property, plant and equipment, etc.), liabilities, owner's equity and statement of profit and loss of the aforesaid subsidiaries have been restated as on the reporting date by applying general price index of the Turkish economy. Considering that the presentation currency of consolidated financial results is ₹, the restatement of comparative figures in consolidated financial results is not required.

7. On 21 July 2026, the Group through its step-down wholly owned subsidiary, Alivira Animal Health Limited, Ireland, has entered into a share purchase agreement with the shareholders of BioForLife Italia S.r.l for acquisition of 100% of its issued and outstanding share capital, subject to the receipt of required approvals, for an aggregate consideration of EURO 16.976 million (including deferred consideration of EURO 1.976 million linked to specified contractual-continuation conditions). Subsequent to the quarter ended 30 September 2026, on receipt of required approvals, the Group has completed the acquisition of 100% of the share capital of BioForLife Italia S.r.l., Milan, Italy. Accordingly, no impact has been given in the financial results for the quarter and half year ended 30 September 2026.

8. Weighted average number of shares considered for calculation of basic and diluted earnings per share for all the periods reported includes the weighted average effect of equity shares and warrants alloted pursuant to the Scheme as described in note 3 above and outstanding share options under employees share option plan.

Viyash Scientific Limited

For Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)

Dr. Hari Babu Bodepudi
Managing Director & Group CEO

Hyderabad, 13 November 2026

S R B C & CO LLP
Chartered Accountants

12th Floor, The Ruby
29 Senapati Bapat Marg
Dadar (West)
Mumbai - 400 028, India
Tel : +91 22 6819 8000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Viyash Scientific Limited (formerly known as Sequent Scientific Limited)

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Viyash Scientific Limited (formerly known as Sequent Scientific Limited) (the "Holding Company") including Sequent Scientific Employee Stock Option Plan Trust (the "Trust") and its subsidiaries (the Holding Company, Trust and its subsidiaries together referred to as "the Group"), for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure 1 to the auditor's review report.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

S R B C & CO LLP
MUMBAI
CHARTERED ACCOUNTANTS

6. We draw attention to Note 3 to the accompanying Statement, which describes that pursuant to the Composite Scheme of Amalgamation (the "Scheme") between the Company and SeQuent Research Limited, Viyash Life Sciences Private Limited and its subsidiaries (individually referred to as "Transferor Company"), as approved by the Hon'ble National Company Law Tribunal vide its order dated November 18, 2025, the Transferor Companies have been amalgamated with the Company. The amalgamation has been accounted for in the manner as prescribed under the Scheme and in accordance with Appendix C of Ind AS 103 - Business Combinations, applicable to business combination of entities under common control. Accordingly, the comparative financial information for the quarter / period ended 30 September 2025 presented in accompanying Statement, has been restated to give effect to the aforesaid amalgamation, as described further in the said note. Our conclusion is not modified in respect of this matter.

7. The accompanying Statement includes the unaudited interim financial results and other unaudited financial information, in respect of:

   - Thirteen subsidiaries, whose unaudited interim financial results include total assets of Rs. 22,908.80 million as at September 30, 2026, total revenues of Rs. 4,244.70 million and Rs. 8,401.90 million, total net profit after tax of Rs. 414.10 million and Rs. 809.00 million, total comprehensive income of Rs. 414.00 million and Rs. 809.00 million for the quarter ended September 30, 2026, and the period ended on that date respectively, and net cash inflow of Rs. 1,854.20 million for the period April 01, 2026, to September 30, 2026, as considered in the Statement which have been reviewed by their respective independent auditors.

   The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

   Certain of these subsidiaries are located outside India whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Holding Company's management has converted the financial results of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the report of other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

8. The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of:

   - Sequent Scientific Employee Stock Option Plan Trust, whose interim financial results and other financial information reflect total assets of Rs. 28.40 million as at September 30, 2026, total revenues of Rs. Nil and Rs. Nil, total net loss after tax of Rs. Nil and Rs. 0.01 million, total comprehensive expense of Rs. Nil and Rs. 0.01 million for the quarter ended



September 30, 2026 and period ended on that date respectively and net cash outflow of Rs. 0.03 million for the period from April 01, 2026 to September 30, 2026 and

- Two subsidiaries, whose unaudited interim financial results and other financial information reflect total assets of Rs. 158.60 million as at September 30, 2026, total revenues of Rs 55.20 million and Rs. 97.90 million, total net loss after tax of Rs. 0.40 million and Rs. 8.80 million, total comprehensive expense of Rs. 0.40 million and Rs. 8.80 million, for the quarter ended September 30, 2026 and the period ended to that date respectively and net cash inflows of Rs. 3.10 million for the period April 01, 2026, to September 30, 2026.

The unaudited interim financial results and other unaudited financial information of the Trust and these two subsidiaries have not been reviewed by any auditor and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement in respect of matters stated in para 7 and 8 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.

For S R B C & CO LLP
Chartered Accountants
ICAI Firm registration number: 324982E/E300003

per Anil Jobanputra
Partner
Membership No.: 110759
UDIN: 26110759MYDLCY3929
Place: Mumbai
Date: November 13, 2026

Annexure 1 to Auditor's report

Name of the Holding Company

1. Viyash Scientific Limited

Including its following subsidiaries:

2. Alivira Animal Health Limited, India
3. Appco Pharma LLC

Including its following subsidiary:

4. Alivira Animal Health Limited, Ireland

Including its following subsidiaries and sub subsidiaries:

5. Vila Viña Participacions, S.L.
6. Laboratorios Karizoo, S.A.
7. Phytotherapic Solutions S.L.
8. Alivira Saude Animal Ltda
9. Alivira Saude Animal Brasil Participacoes Ltda
10. Expeden Distribuidora De Produtos Veterinarios Ltda
11. Provet Veteriner Ürünleri San. Ve Tic. A. Ş.
12. Topkim Topkapi Ilaç premiks Sanayi Ve Ticaret A.Ş.
13. Laboratorios Karizoo, S.A. de C.V. (Mexico)
14. Alivira Animal Health UK Limited
15. Alivira Italia S.R.L.
16. Alivira Animal Health USA LLC
17. Alivira BV
18. N-Vet AB
19. Bremer Pharma GmbH
20. Alivira NV

Including following Trust:

Sequent Scientific Employee Stock Option Plan Trust

S R B C & CO LLP
MUMBAI
CHARTERED ACCOUNTANTS